Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
MV130
BIOLOGICAL
3 trials
Sponsors
Inmunotek S.L.
, Liverpool School of Tropical Medicine
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Immune Response
Respiratory
Phase 1
Study to Evaluate the Ability of Sublingual MV130 to Induce the Expression of Trained Immunity in Peripheral Blood Cells
NCT05208060
Inmunotek S.L.
Immune Response
Start: 2023-09-01
End: 2025-12-31
Target: 48
Updated: 2024-09-19
Phase 2
Evaluation of the Efficacy and Safety of MV130 in Chronic Obstructive Pulmonary Disease (COPD)
Completed
NCT01842360
Inmunotek S.L.
Chronic Obstructive Pulmonary Disease (COPD)
Start: 2013-05-06
End: 2023-08-02
Updated: 2025-10-02
MV130 and Pneumococcal Colonisation in Malawi
Active, not recruiting
PACTR202403820001276
Liverpool School of Tropical Medicine
Respiratory
Start: 2024-04-02
Target: 106
Updated: 2026-08-03
Related Papers
Whole cell inactivated poly-bacterial preparation MV130 effect on nasal mucosal immunity and experimental human pneumococcal carriage: double-blind randomised controlled trial with controlled human infection model.
2026-08-26
Prevention of COPD exacerbations with a mucosal trained immunity-based vaccine (MV130): a randomised phase 3 trial.
2026-07-23